AI Regulatory Affairs Specialist
An AI Regulatory Affairs Specialist ensures that AI- and ML-driven medical devices, digital therapeutics, and clinical decision-su…
Skill Guide
The systematic application of the ISO 14971 risk management process to medical devices, extended with specific risk analysis techniques for hazards arising from the unique failure modes of artificial intelligence components, such as data drift, distributional shift, and automation bias.
Scenario
You are tasked with creating the initial risk management file for a chest X-ray analysis algorithm that is trained on a fixed dataset and not updated post-deployment.
Scenario
A deployed AI algorithm for diabetic retinopathy screening is showing a gradual decline in performance at a new clinic partner, suspected to be due to differences in camera hardware (distributional shift).
Scenario
A company wants to deploy an AI model for predicting patient deterioration that is designed to retrain monthly on new clinical data from the deployment site. The FDA requires a PCCP for the anticipated modifications.
The foundational framework. ISO 14971 provides the process. IEC 62304 governs the software lifecycle. The FDA guidance defines modern expectations for AI/ML, including PCCPs. EU MDR provides the legal safety requirements.
FTA is top-down for system-level hazards. FMEA is bottom-up for component failures (e.g., specific AI model outputs). HTM is the critical document linking hazards to controls and verification. URRA is essential for assessing automation bias and clinician over-reliance.
These tools are used to implement technical risk controls. Track model versions and data lineage. Continuously monitor input data distributions and model performance metrics in production to detect drift and trigger predefined responses.
Answer Strategy
Structure the answer using the ISO 14971 process phases. For the hazards, move beyond generic software risks to concrete AI failure modes. Sample Answer: 'I'd start with intended use definition, then apply both FTA and FMEA. My top three AI-specific hazards would be: 1) **False Negative Leading to Delayed Diagnosis**, traced to a failure in detecting subtle findings due to a lack of representative training data. 2) **Automation Bias Leading to a Missed Finding**, a use-related hazard where the clinician defers to the AI and fails to review the study themselves. 3) **Performance Degradation from Data Drift**, where the model's accuracy declines over time as the patient population or imaging equipment changes without detection.'
Answer Strategy
This tests operational risk management and post-market surveillance. The answer must demonstrate a closed-loop process. Sample Answer: 'Immediately, I would trigger the post-market surveillance protocol: 1) Verify the performance metric and assess if it breaches a predefined acceptance threshold, constituting a safety signal. 2) If so, initiate a correction under the risk management plan, potentially adding a human review step for this site while investigating. Long-term, I'd root-cause the drift-likely a distributional shift in the data. I'd then update the risk management file, adding or modifying this hazard with new controls like site-specific recalibration or data pre-processing, and document the decision-making per ISO 14971.'
1 career found
Try a different search term.